IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9125872 B1

PDFFull Text
Date of Patent:
Sep. 08, 2015

Filed:

Oct. 12, 2010

Polyethylene glycol aerogels for targeted delivery of pharmaceutical drubs

Applicant:

Yosry A. Attia, Delaware, OH (US);

Inventor:

Yosry A. Attia, Delaware, OH (US);

Assignee:

Other;

Attorneys:

Mueller Law, LLC

Jerry K. Mueller, Jr.

Primary Examiner:

Christopher M Babic

Assistant Examiner:

Kelaginamane T Hiriyanna

Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61B 5/055 (2006.01); A61K 31/16 (2006.01); A61K 9/51 (2006.01); A61K 9/70 (2006.01); A61K 31/337 (2006.01); A61K 31/351 (2006.01); A61K 31/40 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/573 (2006.01); A61K 31/7048 (2006.01); A61K 31/7068 (2006.01); A61K 47/10 (2006.01); A61K 49/18 (2006.01);
U.S. Cl.
CPC ...
A61K 31/16 (2013.01); A61K 9/5146 (2013.01); A61K 9/5192 (2013.01); A61K 9/7007 (2013.01); A61K 31/337 (2013.01); A61K 31/351 (2013.01); A61K 31/40 (2013.01); A61K 31/4375 (2013.01); A61K 31/4439 (2013.01); A61K 31/573 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61K 47/10 (2013.01); A61K 49/1803 (2013.01);
Abstract

A polyethylene glycol (PEG) aerogel particles having an average particle diameter not substantially above about 2μ, a volumetric porosity of greater than about 50%, and pore sizes capable of retaining drug molecules. A method for preparing such polyethylene glycol (PEG) aerogel particles includes initiating a catalyzed reaction using a catalyst of PEG forming ingredients to form PEG particles; partially drying the formed PEG particles under conditions to control pore size; and subjecting the partially dried formed PEG particles to COsupercritical extraction for form the PEG aerogel particles. Drug molecules include chemotherapeutic agents. The surface of the PEG aerogel particles are reactable with a variety of agents, for example, to selectively target tumors, protects irreversible damage to labile proteins, and protects degradation of sensitive drugs with subsequent loss of biological efficacy.

Find Patent Forward Citations

Loading…